Literature DB >> 12044011

Oncogenic tyrosine kinases and the DNA-damage response.

Tomasz Skorski1.   

Abstract

Oncogenic tyrosine kinases (OTKs) are involved in the induction of many types of tumour, including haematological malignancies and cancers of the breast, prostate, colon and lung. Neoplastic cells that express OTKs are usually resistant to apoptosis that is induced by DNA-damaging agents, such as cytostatic drugs and irradiation, and they display genomic instability. So, what are the mechanisms involved, and what is the potential for overcoming OTK-mediated resistance in the clinic?

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12044011     DOI: 10.1038/nrc799

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  31 in total

1.  CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.

Authors:  Paula Aranaz; Cristina Hurtado; Ignacio Erquiaga; Itziar Miguéliz; Cristina Ormazábal; Ion Cristobal; Marina García-Delgado; Francisco Javier Novo; José Luis Vizmanos
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

2.  Multipotent hematopoietic cells susceptible to alternative double-strand break repair pathways that promote genome rearrangements.

Authors:  Richard Francis; Christine Richardson
Journal:  Genes Dev       Date:  2007-05-01       Impact factor: 11.361

3.  Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R.

Authors:  Zhi Sheng; Shu-Zong Wang; Michael R Green
Journal:  EMBO J       Date:  2009-02-19       Impact factor: 11.598

Review 4.  Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors.

Authors:  Marjan Yaghmaie; Cecilia Cs Yeung
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

5.  ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1.

Authors:  Kiran Mahajan; Harshani R Lawrence; Nicholas J Lawrence; Nupam P Mahajan
Journal:  J Biol Chem       Date:  2014-08-22       Impact factor: 5.157

6.  MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.

Authors:  Silvia Maifrede; Esteban Martinez; Margaret Nieborowska-Skorska; Daniela Di Marcantonio; Michael Hulse; Bac Viet Le; Huaqing Zhao; Katarzyna Piwocka; Italo Tempera; Stephen M Sykes; Tomasz Skorski
Journal:  Blood Adv       Date:  2017-08-09

7.  Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.

Authors:  Shu-Yue Ren; Elisabeth Bolton; M Golam Mohi; Andrea Morrione; Benjamin G Neel; Tomasz Skorski
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

Review 8.  Genomic instability: The cause and effect of BCR/ABL tyrosine kinase.

Authors:  Tomasz Skorski
Journal:  Curr Hematol Malig Rep       Date:  2007-05       Impact factor: 3.952

9.  Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis.

Authors:  Yong Liao; Mien-Chie Hung
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

10.  Regulation of therapeutic resistance in cancers by receptor tyrosine kinases.

Authors:  Mei-Kuang Chen; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2016-03-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.